Article

ED after prostate cancer treatment may be underreported

Las Vegas-Researchers don't agree on how to measure erectile function and dysfunction, making it difficult to determine the effects of prostate cancer treatment on patients' sex lives, said Johns Hopkins researchers who presented a review of 592 articles at the Sexual Medicine Society of North America fall meeting here.

Related Videos
Closeup of patient with prescription | Image Credit: © gpointstudio - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Landon Trost, MD, answers a question during a Zoom video interview
Anna Myers, CNP, answers a question during a Zoom video interview
Dr Louise Kostos answers a question during a Zoom video interview
1 expert in this video
Perry Xu, MD, answers a question during a Zoom video interview
Related Content
RAG-01 elicits complete responses in NMIBC
March 26th 2025

RAG-01 elicits complete responses in NMIBC

Hannah Clarke
"The striking CR rates observed in these early cohorts are highly encouraging, particularly for BCG-unresponsive NMIBC patients who currently have limited treatment options," says Paul D. Anderson, MBBS, FRACS.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Bel-sar shows promising safety, efficacy in NMIBC
March 26th 2025

Bel-sar shows promising safety, efficacy in NMIBC

Hannah Clarke
In patients with intermediate-risk disease, 4 of 5 patients demonstrated a complete response.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approves gepotidacin for uncomplicated UTI
March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke
The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.
Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC
March 25th 2025

Cretostimogene grenadenorepvec continues to show favorable efficacy, safety in NMIBC

Hannah Clarke
"Now with the new translational data indicating that post-treatment close contact precautions are unnecessary, I am confident that cretostimogene will represent a breakthrough in bladder cancer treatment, if approved by the FDA," says Trinity J. Bivalacqua, MD, PhD.
© 2025 MJH Life Sciences

All rights reserved.